Portal de Periódicos da CAPES

Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis

2021; European Rhinologic Society; Volume: 59; Issue: 1 Linguagem: Inglês

10.4193/rhin20.126

2589-0085

Kachorn Seresirikachorn, Joaquim Mullol, K. Limitlaohaphan, V. Asvapoositkul, Kornkiat Snidvongs,

Olfactory and Sensory Function Studies

Background: Intranasal corticosteroids (INCS) and leukotriene receptor antagonist (LTRA) have different mechanisms of action. The combination of INCS and LTRA (INCS+LTRA) are utilized to control the allergic rhinitis (AR) symptoms. The effects of this com- bination have not been made evident yet. Methodology: Randomized controlled trials studying the effects of INCS+LTRA vs INCS in monotherapy on rhinoconjunctivitis symptoms in patients with AR were included. Data were pooled for meta-analysis. The outcomes were nasal symptoms, ocular symptoms, disease-specific quality of life (QOL), and adverse events. Results: Six studies (358 participants) met the inclusion criteria. There were no differences between INCS+LTRA and INCS mono- therapy on composite nasal symptom score, total daytime symptom score, total night time symptom score, disease-specific QOL and adverse events. The results favoured the effects of INCS-LTRA on ocular symptoms. Conclusions: The effects of the INCS+LTRA combination are not different from INCS in monotherapy in the improvement of both nasal symptoms and patient's QOL. The combination may, however, be better on improving ocular symptoms.